Morepen Labs receives anti-allergy API Loratadine approval for export to China
This marks a Morepen's strategic entry into one of the world's largest pharmaceutical markets.;
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-04-01 05:45 GMT | Update On 2025-04-01 05:45 GMT
Advertisement
Gurugram: Morepen Laboratories Limited has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China for its Loratadine (anti-allergy API).
According to a release, Morepen commands an over 80% market share in the US generics market for Loratadine, making it the undisputed leader in its category. The company has been exporting to the US market for over 25 years, its API exports alone are valued at Rs.650 crores. This approval further solidifies Morepen’s position as the dominant global manufacturer of Loratadine, a widely prescribed second-generation antihistamine and anti-allergy drug used to treat allergic symptoms such as hay fever and chronic urticaria. With this development, Morepen is poised to capture a significant share of the Chinese market while reinforcing its standing in the global pharmaceutical landscape.
“The approval by China’s NMPA is a testament to Morepen’s unwavering commitment to quality, regulatory excellence, and global market expansion,” said Kushal Suri, Director – Sales & Marketing, Morepen Laboratories. “China represents a vast growth opportunity, and this milestone will allow us to meet the increasing demand for high-quality antihistamine and anti-allergy APIs while reinforcing our leadership in global healthcare.”
"Morepen is the number one APIs exporter out of India for six leading products, including Loratadine, Montelukast, Desloratadine, Atorvastatin, Rosuvastatin, and Fexofenadine. The company exports to 82 countries and has a manufacturing capacity of 144 metric tons API annually. With world-class manufacturing facilities at Masulkhana and Baddi, both USFDA-approved, Morepen continues to expand its footprint across regulated and emerging markets, including the US, Europe, Japan, China, and Russia. The company holds 167 patents; 27 USDMFs; 12 CEP filings; 10 China IDLs; 278 other DMFs, and 44 new products in its portfolio. Loratadine also holds approved USDMF, CEP, and IDL China registrations, along with 23 additional other DMFs and three granted patents," the release added.
Morepen Laboratories, established in 1984, is a company in the pharmaceutical and healthcare industry. The Company has a strong presence in APIs, medical devices, and finished formulations.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.